C4 Therapeutics (CCCC) Non-Current Deffered Revenue (2019 - 2025)
Historic Non-Current Deffered Revenue for C4 Therapeutics (CCCC) over the last 7 years, with Q3 2025 value amounting to $19.9 million.
- C4 Therapeutics' Non-Current Deffered Revenue fell 3057.81% to $19.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.9 million, marking a year-over-year decrease of 3057.81%. This contributed to the annual value of $28.5 million for FY2024, which is 3045.29% up from last year.
- C4 Therapeutics' Non-Current Deffered Revenue amounted to $19.9 million in Q3 2025, which was down 3057.81% from $21.2 million recorded in Q2 2025.
- C4 Therapeutics' 5-year Non-Current Deffered Revenue high stood at $50.9 million for Q1 2021, and its period low was $15.8 million during Q1 2023.
- Moreover, its 5-year median value for Non-Current Deffered Revenue was $21.2 million (2025), whereas its average is $24.9 million.
- As far as peak fluctuations go, C4 Therapeutics' Non-Current Deffered Revenue plummeted by 6262.23% in 2022, and later skyrocketed by 4599.19% in 2024.
- Quarter analysis of 5 years shows C4 Therapeutics' Non-Current Deffered Revenue stood at $24.4 million in 2021, then tumbled by 30.67% to $16.9 million in 2022, then grew by 29.12% to $21.8 million in 2023, then skyrocketed by 30.45% to $28.5 million in 2024, then crashed by 30.11% to $19.9 million in 2025.
- Its last three reported values are $19.9 million in Q3 2025, $21.2 million for Q2 2025, and $25.1 million during Q1 2025.